Abnormal expression and signaling of ErbB receptors has been implicated in multiple epithelial malignancies, including pancreatic cancer. Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been recently approved for pancreatic cancer treatment, but there are no reliable predictors of patient response. Expression of additional ErbB receptors seems to influence tumor response to EGFR-targeted therapy. We analyzed the influence of ErbB3 expression on pancreatic cancer cell response to erlotinib treatment. Proliferation assays of five human pancreatic cancer cell lines were performed following treatment with erlotinib. Expression and phosphorylation profiles of ErbB receptors and downstream adaptor protein (Akt, ERK1/2, STAT3, mTOR) were evaluated following stimulation with EGF or neuregulin-b. The formation of EGFR homodimers and EGFR-ErbB3 heterodimers, necessary to enable ErbB3 downstream signaling, was demonstrated by chemical cross-linking assays. The effects of RNA inhibition of ErbB3 on sensitivity to erlotinib treatment were evaluated in AsPC-1 pancreatic cancer cells.
ABSTrACT
Abnormal expression and signaling of ErbB receptors has been implicated in multiple epithelial malignancies, including pancreatic cancer. Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been recently approved for pancreatic cancer treatment, but there are no reliable predictors of patient response. Expression of additional ErbB receptors seems to influence tumor response to EGFR-targeted therapy. We analyzed the influence of ErbB3 expression on pancreatic cancer cell response to erlotinib treatment. Proliferation assays of five human pancreatic cancer cell lines were performed following treatment with erlotinib. Expression and phosphorylation profiles of ErbB receptors and downstream adaptor protein (Akt, ERK1/2, STAT3, mTOR) were evaluated following stimulation with EGF or neuregulin-b. The formation of EGFR homodimers and EGFR-ErbB3 heterodimers, necessary to enable ErbB3 downstream signaling, was demonstrated by chemical cross-linking assays. The effects of RNA inhibition of ErbB3 on sensitivity to erlotinib treatment were evaluated in AsPC-1 pancreatic cancer cells.
Erlotinib inhibited Akt phosphorylation and proliferation of all the ErbB3-expressing cell lines but did not affect mTOR activation. Cross-linking studies confirmed the presence of EGFR-ErbB3 heterodimers in pancreatic cancer cells. Only the ErbB3-deficient MIA PaCa-2 cells displayed persistent Akt activation and ongoing proliferation in spite of erlotinib treatment. siRNA-mediated inhibition of ErbB3 expression in AsPC-1 cells resulted in acquired resistance to erlotinib treatment. Pancreatic cancer cells which lack ErbB3 do not display activation of the ErbB3-PI3K-Akt cascade induced by EGFR/ErbB3 heterodimers and become less critically dependent on EGFR signaling and therefore resistant to erlotinib. Pancreatic cancer expression of ErbB3 may be useful for EGFR-targeted therapy patient selection.
InTroDuCTIon
Pancreatic cancer remains the fourth deadliest cancer in the United States, with an estimated 33,730 new cases and 32,300 deaths in 2006. 1 The vast majority of pancreatic cancer patients succumb to metastatic disease, and five-year overall survival rates remain below 5%. Erlotinib is a small-molecule EGFR-TKI that was recently approved for pancreatic cancer patient treatment in combination with gemcitabine. The significant, though modest, increase in median survival offered by the erlotinib/gemcitabine combination illustrates both the potential and the challenges of anti-EGFR therapy in patients with unresectable pancreatic cancer. 2 There is a clear need to better select a subset of pancreatic cancer patients who could benefit the most from EGFR-targeted therapy.
The ErbB family of receptors consists of four receptor tyrosine kinases (RTK), epidermal growth factor receptor (EGFR or ErbB1), ErbB2, ErbB3, and ErbB4. EGFR has several ligands, including EGF, TGFa and Heparin Binding-EGF. Various isoforms of the neuregulins (NRG) serve as ligands for ErbB3 and ErbB4. ErbB2 lacks a known ligand. 3, 4 As RTK's, ErbB receptors exist as monomers in the cell membrane. Ligand binding induces homo-and heterodimerization of these receptors, resulting in autophosphorylation of their cytoplasmic domains with the consequent signal amplification. 5 For example, EGFR activation by EGF leads to activation of ErbB2 by transduction through heterodimerization. 6 Numerous studies have demonstrated that stimulation with EGF or NRG also induces other members of the ErbB family to form hetero-oligomers. 5, 7 Abnormal signaling by the ErbB family network has been implicated in the etiology and tumorigenesis of several types of human malignancies.
Overexpressed in approximately 60% of pancreatic cancers, 8 the ErbB receptors have presented a logical target for systemic therapy. First identified by its TK homology with EGFR and ErbB2, ErbB3's overexpression suggests a role in epithelial cancer progression. 9 Since the ErbB3 catalytic domain shows very weak, if any, kinase activity, it is an obligate heterodimerization partner. 10 In addition, ErbB3 couples with phosphoinositide 3-kinase (PI3K) to activate the Akt signaling cascade. It contains six tyrosine phosphorylation sites with YXXM motifs that serve as binding sites for PI3K. 11, 12 ErbB receptor dimerization plays an important role in ErbB receptor biology since it provides broad signal amplification and diversification. 13 The understanding of ErbB3 role in tumorigenesis is rapidly evolving. It has been shown that EGFR alone is unable to promote cellular transformation in NIH 3T3 cells, while coexpression with ErbB3, coupled with stimulation with NRG, induces cellular transformation. 14 It has also been proven that ErbB3 likely promotes HER2-dependent breast carcinogenesis and that downregulation of ErbB3 leads to G 1 arrest and decreased Akt phosphorylation in SKBR3 cells. 15 Engelman et al. have recently shown that inhibition of ErbB3 expression specifically leads to diminished Akt activation in NSCLC cell lines sensitive to gefitinib (another EGFR-small molecule TKI), and that ErbB3 is used to couple EGFR to the PI3K-Akt pathway in these cell lines regardless of EGFR mutation status. 16 Thus, ErbB3 has been shown to mediate PI3K activity and Akt phosphorylation in NSCLC with a possible role as marker of sensitivity to gefitinib. Assessment of ErbB3 expression may therefore help predict NSCLS patients who are likely to benefit from EGFR TKI therapy. 17 On the other hand, studies in ovarian and head and neck carcinomas have linked expression of ErbB3 with worse clinical prognosis and resistance to EGFR inhibition. 18, 19 While ErbB3 does seem to influence tumor proliferation and anti-EGFR drug resistance, its exact influence seems to be tumor type-specific, pointing out the need to explore its role in pancreatic carcinoma.
Via heterodimerization, ErbB3 may function as a platform for recruiting additional intracellular signaling cascades resulting from its trans-phosphorylation by other members of the EGFR family. 7 Prior studies have shown the preferential trend of dimerization for each member of the ErbB family and the corresponding activation pattern of downstream adaptor proteins. 20, 21 While ErbB2 is generally considered the preferential heterodimerization partner for both EGFR and ErbB3, its role in pancreatic cancer may be limited due to low levels of ErbB2 expression. 22 Therefore, the relative role of other dimers in pancreatic cancer may be increased by the diminished involvement of ErbB2. The ErbB receptor homodimers or heterodimers that may modulate and preferentially increase pancreatic cancer dependence on the EGFR pathway have not been identified. The identification of such molecular markers of tumor signaling pathway dependence may be an important tool in the selection of pancreatic cancer candidates for EGFR-targeted therapeutic approaches.
Here we suggest that both pancreatic cancer EGFR pathway dependence and TKI sensitivity are influenced by EGFR heterodimerization with ErbB3. To demonstrate this, we analyzed the EGFR-ErbB3 interaction in pancreatic cancer cells and examined the potential role of this interaction with sensitivity to EGFR-targeted therapy with erlotinib. We also examined the biological properties of these cell lines, at baseline, following ligand stimulation, and following erlotinib therapy, to explore possible biomarkers of EGFR pathway dependence that could correlate with anti-EGFR drug sensitivity. We then sought to demonstrate the presence of EGFR-ErbB3 heterodimers and their influence on EGFR-mediated signaling and thus tumor dependence. As proof of concept, we then inhibited pancreatic cancer cell expression of ErbB3 to further analyze its impact on EGFR pathway dependence and TKI sensitivity.
MATErIAlS AnD METHoDS
Cell culture and drug treatment. AsPC-1, BxPC-3 and MIA PaCa-2 cells were obtained from ATCC (Rockville, MD). S2013 and S2VP10 cells were a gift from Dr. Michael Hollingsworth and were grown in DMEM media supplemented with 10% FBS. Erlotinib (Tarceva R , OSI Pharmaceuticals, Melville, NY, and Genentech, San Francisco, CA) was purchased from the UAB pharmacy and was dissolved in DMSO to a stock concentration of 10 mM. Upon reaching 80% confluence, cells were serum-starved overnight and treated with erlotinib for 4 hours, after which they were stimulated with either 0.1 mg/ml EGF (Sigma-Aldrich, St. Louis, MO) or 0.22 mg/ml NRG-b (Sigma-Aldrich, St. Louis, MO) for 10 minutes. Erlotinib was added directly to the media to achieve a final concentration of 12 mM.
Cell proliferation assay. Two x 10 5 cells were plated in growth medium. Upon attachment, cells were treated with erlotinib (12 mM). Viable cell counts were performed at 48 hours after the initial drug treatment. Treatments were performed in triplicate and repeated in five independent experimental series. Trypan blue staining was performed to verify cell viability.
Immunoblotting. Protein lysates were prepared, and standard SDS-PAGE was performed as previously described. 23 Except for anti-pEGFR (Tyr 1173) (Upstate Biotechnology, Lake Placid, NY), anti-pEGFR (Tyr 1068) (Sigma-Aldrich), anti-EGFR (Sigma-Aldrich), and b-Actin (Sigma-Aldrich), all primary antibodies were obtained from Cell Signaling Technology (Beverly, MA). All primary antibodies were diluted 1:1000. Mouse brain lysates were used as a positive control for ErbB4 antibody. EGF-treated A431 cells were used as a positive control for pErbB2 (Tyr 877), pErbB2 (Tyr 1221/1222) and pEGFR (Tyr 1068) antibodies.
Cross-linking of ErbB receptors. The cross-linking of the receptors was performed as previously described. 24 Cells were stimulated with either 0.1 mg/mL EGF or 0.22 mg/mL NRGb. The cells were then incubated in a 3 mM solution of the cross-linking reagent bis(sulfosuccinimidyl) (BS 3 ) for 20 minutes at 4˚C. Standard SDS-PAGE was subsequently performed.
EGFR and ErbB3 knockdown by siRNA. ErbB3 and EGFR Stealth™ Select RNAi Set oligomers were obtained from Invitrogen (Carlsbad, CA) and used as directed. Vehicle, non-specific, scrambled control experiments were performed in parallel using Stealth™ RNAi Negative Control LO GC (Invitrogen). After a 48 hour growth period following the transfection, cells were treated with erlotinib (12 mM) for another 48 hours, in parallel fashion to the earlier cell proliferation assays. At this time, the cells were either stimulated with EGF (0.1 mg/ml for 10 minutes) and harvested for immunoblotting or used for cell proliferation assay. Each experiment was performed in triplicate.
Statistical methods. Numerical data are presented as mean ± standard deviation (SD). For relative cell proliferation graphs, error bars were calculated by propagation of errors method. Error was calculated as Dz, with, where y is the control value, x is the treatment value, z = x/y, Dy is the SD of the control, and Dx is the SD of the treatment assay.
rESulTS
Treatment with erlotinib inhibits pancreatic cancer cell proliferation in all cell lines except MIA PaCa-2. We sought to study the anti-proliferative effects of erlotinib on a panel of pancreatic cancer cell lines. The proliferation of all cell lines except Mia PaCa-2 was inhibited by erlotinib, relative to controls (Fig. 1) . Accounting for all cell lines' independent runs, the number of cells in AsPC-1, BxPC-3, S2VP10, and S2013 erlotinib treatment groups, were significantly decreased from their respective untreated controls (p < 0.01). The degree of proliferation inhibition of the erlotinib-sensitive cell lines ranged from a high of 52 ± 6% (S2VP10) to a low of 77 ± 2% (BxPC-3), relative to their respective controls. MIA PaCa-2 proliferation did not change following erlotinib treatment and was measured at 103 ± 9%. Interestingly, cell proliferation resumed upon removal of erlotinib from the cell culture media, confirming its role as a cytostatic drug. Erlotinib by itself is not cytotoxic and has a very modest effect on induction of apoptosis that has been extensively documented and characterized by other authors. 25, 26 Effects of erlotinib on the EGFR pathway activation status. All pancreatic cancer cell lines displayed appreciable levels of EGFR and ErbB2 protein ( Fig. 2A and B) , with none expressing ErbB4 ( Fig.  2A and B) . In addition, MIA PaCa-2 was the only cell line with undetectable levels of ErbB3 protein expression. Using IHC, we have previously shown that pancreatic cancer cells express significant amounts of EGF and NRGb and this expression is specific to cancer cells and not the surrounding stroma (unpublished data). We then sought to study the inhibitory mechanisms of erlotinib on ligandspecific ErbB receptor activation and their downstream signaling using our panel of nine pancreatic cell lines. In order to eliminate unwanted activating effects of FBS, we serum-starved the cells overnight, pretreated them with erlotinib and then introduced specific EGFR and ErbB3 receptor ligands (EGF and NRGb, respectively). We performed a comprehensive analysis of the activation status of Fig. 2A and 2B) . Similar to what was described for the phosphorylation of previously mentioned tyrosine residues, Tyr 1173 did not display observable phosphorylation differences between the control and treated groups or between the EGF-and NRG-b-stimulated groups. We did not detect any phosphorylation at either Tyr 877 or Tyr 1248 in the ErbB2 tyrosine kinase domain in any of the cell lines ( Fig. 2A and 2B) . Fig. 2A and B) .
ERK1/2 was strongly phosphorylated in S2013, AsPC-1 and BxPC-3 cells, regardless of ligand stimulation. In the EGF-stimulated groups among these three cell lines, there was a significant reduction in ERK1/2 activation in the erlotinib-treated cells, while the NRG-stimulated groups did not show such a dramatic decrease. The S2VP10 and Mia PaCa-2 cells showed very little baseline ERK1/2 phosphorylation regardless of EGF or NRGb ligand stimulation. All pancreatic cancer cell lines showed variable levels of Akt phosphorylation in the untreated control groups. In the erlotinib-treated cells, there was a substantial decrease in Akt phosphorylation among the NRG-b-stimulated S2VP10, and in all BxPC-3 and AsPC-1 cells. Notably, erlotinib inhibited Akt phosphorylation in all remaining treatment groups except for MIA PaCa-2 cells, in which Akt activation was not affected by the drug. We did not detect STAT3 phosphorylation in any of the cell lines. In turn, mTOR was activated in all cell lines but its phosphorylation levels were not affected by erlotinib treatment, except in BxPC-3 cells (Fig. 2A) .
EGFR-ErbB3 heterodimerization. Since receptor tyrosine kinases must dimerize in order to launch a signaling cascade, we sought to elucidate the ErbB dimers involved in the proliferation of pancreatic cancer cells. After stimulating the cells with either EGF or NRGb, we covalently bound the dimers with Bis(Sulfosuccinimidyl)suber ate (BS 3 ) to preserve the cross-linking. BS 3 is a homobifunctional, water-soluble, non-cleavable and membrane impermeable crosslinker that is specifically used to identify receptor dimerization, shows greater specificity than immunoprecipitation, and is ideal for cell-surface crosslinking. 27 After resolving the proteins and probing for the ErbB receptors, we were able to observe both the ErbB monomers and dimers as they existed. All cell lines showed evidence of EGFR homodimerization, and all cell lines, except MIA PaCa-2, showed evidence of ErbB3 participation in heterodimerization. This was to be expected since MIA PaCa-2 does not express ErbB3. Although all cell lines express ErbB2, and ErbB2-ErbB3 is suppose to be the most potent heterodimer in the ErB family, 28 we observed no evidence of ErbB2 dimerization in these pancreatic cancer cell lines. The visualized dimers we detected must therefore be EGFR-EGFR homodimers and EGFR-ErbB3 heterodimers, because ErbB3 does not form homodimers 10 and ErbB4 was not expressed in any of the 
© 2 0 0 7 L A N D E S B I O S C I E N C E . D O N O T D I S T R I B U T E .
www.landesbioscience.com
Cancer Biology & Therapy e4
ErbB3 Expression and Dimerization Pancreatic Cancer tested cell lines. Furthermore, on the EGFR-probed blots, we saw two bands within the range of the dimers, approximately 10 kDa apart. The upper band at ~350 kDa arguably corresponds to the expected location of the EGFR-ErbB3 heterodimer, with the lower band at ~340 kDa represents the EGFR-EGFR homodimer. As expected, MIA PaCa-2 cells only display an EGFR homodimer in the dimer region (Fig. 3A) . The extent of ErbB dimerization appeared to be affected by the type of stimulating ligand. We saw greater dimerization among the EGF-stimulated cells compared to those receiving NRGb, while the total amount of receptor monomers expectedly remained the same regardless of ligand stimulation.
Effects of erlotinib on pancreatic cancer cell ErbB receptor dimerization. We then investigated whether treating the cells with erlotinib or cetuximab (monoclonal antibody against EGFR) could disrupt the dimerization of ErbB receptors. We sought to prove that the mechanism of TKI sensitivity did not rely on affecting the total number of dimers formed. Our results suggested that treatment with these therapeutic agents regardless of ligand stimulation does not directly affect heterodimerization (Fig. 3B and C) .
siRNA inhibition of ErbB3 induces erlotinib resistance. As a proof of concept, we aimed to directly influence pancreatic cancer cell erlotinib sensitivity by reducing ErbB3 expression in an erlotinib-sensitive line, AsPC-1. We sought to manipulate the response of AsPC-1 cells to erlotinib treatment, expecting a lack of response similar to our findings for the erlotinib-resistant cell line, MIA PaCa-2. Transfected AsPC-1 cells were resistant to erlotinib treatment, with cell proliferation similar to that of MIA PaCa-2 cells (103 ± 12% relative growth, Fig. 4A ). As expected, AsPC-1 without RNA interference displayed erlotinib sensitivity, with 73±9% relative growth. Immunoblot confirmed the suppression of ErbB3 expression and a lesser inhibition of Akt activation in the ErbB3 siRNAtransfected AsPC-1 cells (Fig. 4B) . Interestingly, inhibition of ErbB3 in the absence of erlotinib, did not affect growth, indicating pancreatic cancer cell proliferation is not dependent on ErbB3 alone (Fig. 4A) .
Simultaneous siRNA knockdown of EGFR and ErbB3 decreases cell proliferation. To further analyze the extent of pancreatic cancer cell dependence on aberrant EGFR signaling, we simultaneously treated AsPC-1 cells with both EGFR and ErbB3 siRNA. While the knockdown of ErbB3 alone does not significantly affect pancreatic cancer cell proliferation, the simultaneous inhibition of EGFR and ErbB3 does decrease cell proliferation to a relative level of 57±4% compared to the vehicle control group. As expected, the scrambled control-transfected cells treated with erlotinib displayed typical TKI sensitivity, with relative inhibition of cell proliferation down to 70±6% (consistent with what was observed for the erlotinib-treated vehicle control in the ErbB3-alone siRNA experiment). Following successful siRNA inhibition of both EGFR and ErbB3, the untreated and the erlotinib-treated cells displayed similar proliferation curves (Fig. 5A) . Interestingly, simultaneous knockdown of EGFR and ErbB3 totally abolished the activation of Akt even in the untreated cells, providing evidence for an EGFR-mediated mechanism of Akt activation, independent of the ErbB3-PI3K pathway (Fig. 5B) . The effects of EGFR siRNA inhibition in the ErbB3-deficient MIA PaCa-2 cells further support this observation (Fig. 5C ).
DISCuSSIon
Overexpressed in the majority of pancreatic cancers, the ErbB family of receptors provides a series of logical targets for treatment with specific inhibitors. Here we sought to determine the molecular events triggered by the small-molecule EGFR TKI erlotinib and its effect on pancreatic cancer cell proliferation. We demonstrated that all erlotinib sensitive cells express both activated EGFR and ErbB3 and that ErbB3 may serve as a response marker to erlotinib therapy. Erlotinib inhibition of EGFR signaling is likely to be mediated through ErbB3 transactivation by EGFR, since erlotinib abolished the activation of ErbB3 without being a direct inhibitor of it. We also demonstrated that this EGFR-mediated inhibition of ErbB3 signaling is most likely due to disruption of EGFR-ErBB3 heterodimer. Past studies have proven the baseline existence of EGFR-EGFR, EGFR-ErbB2, ErbB2-ErbB3 and EGFR-ErbB3 homodimers and heterodimers. 29 While ErbB2 has been proposed as a "master conductor of dimerization" 20 we did not find evidence of ErBB2 heterodimerization in pancreatic cancer. ErbB2 was expressed by all our cell lines but it was not activated and remained in monomeric form as EGFR seemed to prefer heterodimerization with ErbB3 or homodimerization with itself. Normally, ErbB3, which lacks sufficient tyrosine kinase domain for pathway activation, actively seeks EGFR or ErbB2, forgoing homodimerization. 10 Although extremely weak, ErbB3's TK activity is not totally absent, 30 with one study showing enough remaining activity to autophosphorylate ErbB2-ErbB3 heterodimers. 10 In addition, the mutation of part of the ErbB3 TK domain decreased ErbB2 activation in an ErbB2-ErbB3 construct in another study. 31 In our pancreatic cancer lines, ErbB3 required EGFR, not ErbB2, for heterodimerization. ErbB3, with its weak TK activity, seems to contribute to self-activation of the EGFR-ErbB3 complex and the downstream EGFR signal transduction pathway. In its usual setting, EGFR homodimers do not self-activate and do not cross-activate, relying on one of several ligands for stimulation and normal activation. 21, 32 EGFR pathway tumor dependence relies on several possible forms of aberrant constitutive activation that include aberrant ligand stimulation, 33 gene amplification 34 and activating mutations. [35] [36] [37] Pancreatic cancer EGFR pathway dependence hinges on factors other than activating mutations, since EGFR has been shown to be highly conserved in this type of tumor (Tzeng 2007, in press). While ligand stimulation and gene copy number can be contributing factors to aberrant EGFR pathway activation, the affinity of ErbB3 for EGFR heterodimerization seems to be an important factor contributing to pancreatic cancer cell EGFR signaling amplification. Through chemical cross-linking studies, we visualized the appropriate EGFR homodimers across different pancreatic cancer cell lines. We then demonstrated the presence of EGFR-ErbB3 heterodimers in all the pancreatic cancer cell lines except MIA PaCa-2, which lacks ErbB3 expression. Therefore, we propose a plausible bidirectional mechanism where ErbB3 contributes to the activation of the EGFR TK domain and triggers the activation of the downstream EGFR pathway. At the same time, EGFR activates PI3K via ErbB3, resulting in the subsequent downstream activation of Akt. When cells are treated with erlotinib, the four cell lines which express ErbB3 show erlotinib sensitivity with inhibition of proliferation. MIA PaCa-2 cells lack detectable ErbB3 protein and exhibit pronounced erlotinib resistance. These results suggest that in the absence of ErbB3 with a resultant lack of EGFR-ErbB3 heterodimers, MIA PaCa-2 cells do not display EGFR pathway dependence. By possibly relying on alternative growth signaling cascades, MIA PaCa-2 cells become resistant to EGFR-TKI treatment. By contrast, in the four pancreatic cancer cell lines that do express ErbB3, EGFR-ErbB3 heterodimers allow constitutive activation of the EGFR TK domain and a greater tumor dependence on this mechanism for growth signaling. ErbB3-siRNA transfection of pancreatic cancer cells does not affect cell proliferation in the absence of erlotinib. However, with siRNA silencing of ErbB3 expression, pancreatic cancer cells become resistant to erlotinib and mimic the behavior of MIA PaCa-2 cells. Double knock-down of EGFR and ErbB3 with subsequent erlotinib treatments further demonstrate that the effects of erlotinib on EGFR receptor activation and the inhibition of EGFR by siRNA have very different effects on cell proliferation and do not represent equivalent events. These findings suggest that the EGFR pathway plays a significant role in pancreatic cancer cell proliferation and that, expectedly, erlotinib does not further inhibit proliferation in the absence of its target, EGFR. Inhibition of EGFR expression induced by siRNA alters dependency on the EGFR pathway for tumor proliferation and the degree of this growth arrest is much stronger than that of erlotinib alone. Erlotinib by itself, though a specific EGFR TK inhibitor, has a less pronounced effect on proliferation than EGFR-siRNA since it does not completely abolish EGFR phosphorylation and it does not induce a complete shutdown of the EGFR signaling pathway. Our conclusion is that the absence of ErbB3 is what renders ineffective pancreatic cancer cell treatment with erlotinib.
Erlotinib has a relatively modest effect on pancreatic cancer cell proliferation, suggesting that pancreatic cancer cells also rely on ErbB-independent proliferation and anti-apoptosis pathways. This provides the rationale for combination strategies with other chemotherapeutic and biologically targeted agents. We acknowledge that there is probably a wide spectrum of responses to anti-EGFR treatment strategies among a heterogeneous population of pancreatic cancers. We propose that pancreatic cancer patients with greater tumor dependence on the EGFR pathway may display greater clinical response rates to EGFR TKI's, allowing for both tumor response and improved overall survival. Our findings provide direct evidence of preferential pancreatic cancer cell EGFR-ErbB3 heterodimerization and its association with TKI sensitivity. The in vitro inhibition of ErbB3 expression by RNA interference seems to result in decreased EGFR heterodimerization and signal amplification, decreased tumor cell EGFR pathway dependence, and resistance to erlotinib therapy. Analysis of ErbB3 expression in pancreatic cancer biopsy specimens may provide a valid selection criterion for patients who are candidates for erlotinib treatment. 
